A new CPAP (continuous positive airway pressure) device from Philips Respironics could enable people with obstructive sleep apnoea (OSA) to manage their own condition more effectively.
The new REMstar Pro (pictured) with AutoIQ is able to track the patient’s sleep breathing over several nights, establish or readjust to a set airway pressure, and check back periodically to adjust the pressure as needed – without clinician intervention.
The first phase of the AutoIQ mode, Auto-Trial, uses an algorithm for a total of 30 days to establish the patient’s treatment needs. At the end of the phase, the device analyses the data to identify and deliver the best airway pressure for the patient.
Following that, Auto-Check checks back every 30 hours to see how the patient is progressing and to automatically adjust the pressure if needed.
Auto-Trial days can be saved to reassess therapy at a later date if the patient’s physical condition or sleeping environment changes.
Throughout the process, AutoIQ keeps the care team informed of the patient’s sleep breathing performance and CPAP compliance.
“REMstar Pro with AutoIQ demonstrates our ongoing pledge to providers and their patients to be their ally in better sleep and breathing,” said John Frank, General Manager for Sleep and Respiratory Care, Philips Home Healthcare Solutions.
“By providing intelligent solutions and advancements in technology, we are shaping the future of sleep therapy.”
Philips Respironics is a unit of Royal Philips Electronics of the Netherlands, a market leader in cardiac care, acute care and home healthcare.